Pharos Capital Launches Verdi Oncology through Horizon Oncology Acquisition

We represented Pharos Capital Group in its acquisition of Horizon Oncology. The acquisition marks the launch of Verdi Oncology, Inc., an oncology practice and clinical research management company. Financial terms of the transaction were not publicly disclosed.

Horizon Oncology offers a wide range of comprehensive cancer services to patients, including advanced technological options, premier clinical expertise and cutting edge clinical trials opportunities, with a focus on early phase trials.

Pharos Capital Group is an SEC Registered Investment Advisor. As of March 2018, Pharos has invested in 51 companies and currently has over $690 million of private equity assets under management.

You Also May Be Interested In:

  • Representing the independent Special Committee of Strategic Storage Growth Trust, Inc. (SSGT), in its definitive agreement to merge with Strategic Storage Trust II, Inc., (SST II) in an all-cash merger valued at $340 million expected to close during the first quarter of 2019, subject to customary closing conditions, including the approval of SSGT’s stockholders

    We are representing the independent Special Committee of Strategic Storage Growth Trust, Inc. (SSGT), in its definitive agreement to merge...
    Client Type: Private Company
  • Represented Wright Medical Group in its acquisition of Cartiva, Inc.

    We served as lead counsel to Wright Medical Group N.V. (Nasdaq: WMGI) in the acquisition of Cartiva, Inc., a privately-held...
    Client Type: Public Company
  • We represented NN, Inc. (Nasdaq: NNBR) in its public offering of 14,375,000 shares of common stock, which was composed of...
    Client Type: Public Company